according to Regulation (EC) No. 1907/2006



### **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Montelukast Granules Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS

: EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

215-631-6999

#### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

#### 2.3 Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

#### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

### Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

Montelukast | 151767-02-1 | Eye Irrit. 2; H319 | >= 0.1 - < 1

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : No special precautions are necessary for first aid responders.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- : Avoid generating dust; fine dust dispersed in air in sufficient

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: Date of last issue: 13.09.2019 SDS Number: 2.15 23.03.2020 23000-00018 Date of first issue: 17.10.2014

concentrations, and in the presence of an ignition source is a fighting

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary. Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Follow safe handling advice and personal protective equip-

ment recommendations.

6.2 Environmental precautions

Discharge into the environment must be avoided. **Environmental precautions** 

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

### **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
Montelukast	151767-02- 1	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm <sup>2</sup>	Internal

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

#### 8.2 Exposure controls

### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices)

Minimize open handling.

### Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

### **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Appearance : powder

Colour : No data available
Odour : No data available
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

Upper explosion limit / Upper :

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available Partition coefficient: n- : No data available

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : No data available

# **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

#### **SECTION 11: Toxicological information**

# 11.1 Information on toxicological effects

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

### **Components:**

Montelukast:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 5,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

#### Skin corrosion/irritation

Not classified based on available information.

# **Components:**

Montelukast:

Species : Rabbit

Result : Mild skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

# **Components:**

Montelukast:

Species : Rabbit

Result : Severe irritation

according to Regulation (EC) No. 1907/2006



### **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

Montelukast:

Remarks : No data available

#### Germ cell mutagenicity

Not classified based on available information.

#### **Product:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

#### **Components:**

Montelukast:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

### Carcinogenicity

Not classified based on available information.

**Product:** 

Species : Rat
Application Route : Oral
Exposure time : 2 Years

Dose : 200 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks

Dose : 100 mg/kg body weight

Result : negative

#### **Components:**

Montelukast:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species: MouseApplication Route: OralExposure time: 92 weeksResult: negative

# Reproductive toxicity

Not classified based on available information.

**Product:** 

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: NOAEL Parent: 800 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: LOAEL Parent: 200 mg/kg body weight

Symptoms: Reduced fertility

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

### **Components:**

#### Montelukast:

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 800 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: LOAEL: 200 mg/kg body weight

Symptoms: Reduced fertility

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: NOAEL: 100 mg/kg body weight

Symptoms: Reduced fertility

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### **Components:**

#### Montelukast:

Species : Monkey, male and female

NOAEL : 150 - 300 mg/kg

Application Route : Oral Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

#### **Aspiration toxicity**

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

### **Experience with human exposure**

**Product:** 

Skin contact : Remarks: May irritate skin. Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,

Headache, Cough, Abdominal pain, Diarrhoea, Fever

**Components:** 

Montelukast:

Skin contact : Remarks: May irritate skin. Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,

Headache, Cough, Abdominal pain, Diarrhoea, Fever

### **SECTION 12: Ecological information**

### 12.1 Toxicity

#### **Components:**

Montelukast:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/i

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.073 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

NOEC: 0.0816 mg/l Exposure time: 7 d

Species: Cyprinodon variegatus (sheepshead minnow)

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.23 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Remarks: No toxicity at the limit of solubility

#### 12.2 Persistence and degradability

#### **Components:**

Montelukast:

Biodegradability : Result: not rapidly degradable

Biodegradation: 0 % Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21.7 h)

### 12.3 Bioaccumulative potential

### **Components:**

Montelukast:

Partition coefficient: n-

:  $\log Pow: > 4.3$ 

octanol/water

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

Not relevant

#### 12.6 Other adverse effects

No data available

## **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

### **SECTION 14: Transport information**

#### 14.1 UN number

Not regulated as a dangerous good

### 14.2 UN proper shipping name

Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

Not regulated as a dangerous good

#### 14.4 Packing group

Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

#### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

: Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de- : Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EC) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to Regulation (EC) No. 1907/2006



### **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

**Full text of H-Statements** 

H319 : Causes serious eye irritation.

Full text of other abbreviations

Eye Irrit. : Eye irritation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx -Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx -Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration: ICAO - International Civil Aviation Organization: IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

according to Regulation (EC) No. 1907/2006



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 23.03.2020 23000-00018 Date of first issue: 17.10.2014

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN